Daniel J. Lettiere
Pfizer (United States)(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Monoclonal and Polyclonal Antibodies Research, Lung Cancer Treatments and Mutations, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor(2008)221 cited
- → A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor(2022)146 cited
- → Discovery of Two Clinical Histamine H 3 Receptor Antagonists: trans - N -Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]- N -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)(2011)107 cited
- → Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls)(2022)10 cited
- → Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity(2021)7 cited
- → Renal and Hematologic Comparative Effects of Dissociated Agonist of the Glucocorticoid Receptor and Prednisone in Dogs With and Without Food Restriction(2018)6 cited
- → Spontaneous unilateral renal dysplasia in a clinically healthy cynomolgus monkey (Macaca fascicularis)(2014)3 cited
- → Data from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor(2023)
- → Supplementary Fig. S4 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor(2023)